Edgar Filing: BUCHEN DAVID A - Form 4

DUCHEN DAVID

Form 4	AVIDA										
August 13, 2	.009										
FORM	14 UNITE					NGE C	COMMISSION	OMB AF OMB Number:	PROVAL 3235-0287		
Check the		Washington, D.C. 20549							Expires:	January 31,	
if no long subject to Section 1 Form 4 o Form 5 obligation	6. r Filed p	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,								2005 Iverage rs per 0.5	
may cont See Instru 1(b).	tinue. Section 1		Public Ut of the In	-	-			1935 or Section	n		
(Print or Type I	Responses)										
BUCHEN DAVID A S			Symbol	Name and ON PHAR PI]			-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)(First)(Middle)3. Date of (Month/E)C/O WATSON08/12/20PHARMACEUTICALS, INC., 31108/12/20BONNIE CIRCLE08/12/20				-	ansaction			Director 10% Owner _X Officer (give title Other (specify below) Sr. VP, General Counsel & Sec.			
				ndment, Date Original nth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	lv Owned	
1.Title of Security (Instr. 3)	2. Transaction D (Month/Day/Yea	ar) Executio any	med	3. Transactic Code (Instr. 8) Code V	4. Securi on(A) or Di (Instr. 3,	ties A spose	cquired d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of	
Common Stock, par value \$0.0033	08/12/2009			F	298	D	\$ 34.63	38,599 <u>(1)</u>	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: BUCHEN DAVID A - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amou Unde Secur	le and int of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address		Relationships						
		Director	10% Owner	Officer	Other			
BUCHEN DAVID A C/O WATSON PHARMACI 311 BONNIE CIRCLE CORONA, CA 92880	EUTICALS, INC.			Sr. VP, General Counsel & Sec.				
Signatures								
/s/DAVID A. BUCHEN	08/13/2009							

<u>**</u>Signature of Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

Date

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes shares of restricted stock issued pursuant to the Second Amendment and Restatement of the 2001 Incentive Award Plan of Watson Pharmaceuticals, Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.